Capital Analysts LLC’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Analysts LLC’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250	Closed	-$19K	–	1036
2023 Q1	$19K	Buy	+250	New	+$20.7K	﹤0.01%	744
2021 Q2	–	Sell	-20	Closed	-$3K	–	1096
2021 Q1	$3K	Buy	+20	New	+$2.99K	﹤0.01%	940
2020 Q3	–	Sell	-1,500	Closed	-$168K	–	768
2020 Q2	$168K	Hold	1,500	–	–	0.02%	229
2020 Q1	$116K	Sell	1,500 -2,375	-61%	-$210K	0.01%	243
2019 Q4	$369K	Sell	3,875 -4,150	-52%	-$359K	0.04%	198
2019 Q3	$611K	Buy	8,025 +625	+8%	+$51.9K	0.06%	177
2019 Q2	$649K	Buy	7,400 +750	+11%	+$64K	0.07%	174
2019 Q1	$602K	Buy	6,650 +1,650	+33%	+$140K	0.07%	168
2018 Q4	$359K	Buy	+5,000	New	+$403K	0.05%	173

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Capital Analysts LLC's XBI Position: Q2 2023 in Review

Capital Analysts LLC sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 250 shares — an estimated $19K sold.

Capital Analysts LLC first reported a position in XBI in Q4 2018 and held it in 9 quarters. The position peaked at $649K in Q2 2019. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Capital Analysts LLC reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Capital Analysts LLC sold 250 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $19K.
Capital Analysts LLC first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 9 quarters.
Capital Analysts LLC's State Street SPDR S&P Biotech ETF position peaked at $649K in Q2 2019.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Capital Analysts LLC's 13F filing for Q2 2023, filed 11 Aug 2023.